Form 4: Director Receives Shares for Compensation

Gilbert Lynn Marks, a Director at AN2 Therapeutics, Inc., acquired 3,775 shares of common stock as compensation, increasing his beneficial ownership.

Summary

• Gilbert Lynn Marks, a Director at AN2 Therapeutics, Inc. (ANTX), acquired 3,775 shares of common stock on April 10, 2026.
• These shares were issued in lieu of cash compensation under the company's non-employee director compensation policy.
• All acquired shares vest immediately.
• Following this transaction, Mr. Marks beneficially owns 79,084 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard compensation transaction for a director rather than a significant financial event for the company.

Positives

• Director compensation is being provided in the form of equity, aligning director interests with shareholders.
• The shares vest immediately, providing full ownership to the director upon issuance.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that the issuance of equity for director compensation is a common practice in the biotechnology and pharmaceutical sectors, aiming to attract and retain talent while aligning incentives with long-term company performance.

Related Party Transactions

• Acquisition of 3,775 shares of common stock by Director Gilbert Lynn Marks in lieu of cash compensation.

Stakeholder Impact

• Shareholders: The issuance of shares for compensation dilutes existing ownership slightly but aligns director interests with shareholder value creation.
• Employees: This practice can be seen as a positive signal of the company's compensation strategy.
• Management: Reinforces the company's compensation structure for its board members.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Form 4, Director Compensation, Equity Award, Beneficial Ownership, Securities Exchange Act